AlloVir, Inc. (ALVR)
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
$87.47M
Dr. Diana M. Brainard M.D.
107.00
Waltham, MA
Jul 30, 2020
-0.62
$-1.23
44.40
55.08
-1,674.74%
-0.62
0.00
0.72
10.33
55.08
-107.14%
-96.48%
Similar stocks (14)
Crinetics Pharmaceuticals, Inc.
CRNX
Agios Pharmaceuticals, Inc.
AGIO
AnaptysBio, Inc.
ANAB
Cullinan Oncology, Inc.
CGEM
Stoke Therapeutics, Inc.
STOK
4D Molecular Therapeutics, Inc.
FDMT
Lyell Immunopharma, Inc.
LYEL
Black Diamond Therapeutics, Inc.
BDTX
Inhibrx, Inc.
INBX
Acrivon Therapeutics, Inc. Common Stock
ACRV
Kronos Bio, Inc.
KRON
Aerovate Therapeutics, Inc.
AVTE
Anebulo Pharmaceuticals, Inc.
ANEB
AN2 Therapeutics, Inc.
ANTX
ETF Exposure (6)
Schwab U.S. Small-Cap ETF
SCHA
0.0013363827%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (14)
Crinetics Pharmaceuticals, Inc.
CRNX
Agios Pharmaceuticals, Inc.
AGIO
AnaptysBio, Inc.
ANAB
Cullinan Oncology, Inc.
CGEM
Stoke Therapeutics, Inc.
STOK
4D Molecular Therapeutics, Inc.
FDMT
Lyell Immunopharma, Inc.
LYEL
Black Diamond Therapeutics, Inc.
BDTX
Inhibrx, Inc.
INBX
Acrivon Therapeutics, Inc. Common Stock
ACRV
Kronos Bio, Inc.
KRON
Aerovate Therapeutics, Inc.
AVTE
Anebulo Pharmaceuticals, Inc.
ANEB
AN2 Therapeutics, Inc.
ANTX
ETF Exposure (6)
Schwab U.S. Small-Cap ETF
SCHA
0.0013363827%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%